Humasis Co. Ltd. (KOSDAQ:205470)
South Korea · Delayed Price · Currency is KRW 1,000.00
-36.00 (-3.47%)
Jan 30, 2026, 3:30 PM KST
Humasis Revenue
Humasis had revenue of 8.65B KRW in the quarter ending September 30, 2025, a decrease of -17.91%. This brings the company's revenue in the last twelve months to 35.60B, up 114.87% year-over-year. In the year 2024, Humasis had annual revenue of 25.41B with 83.79% growth.
Revenue (ttm)
35.60B
Revenue Growth
+114.87%
P/S Ratio
3.18
Revenue / Employee
515.97M
Employees
69
Market Cap
113.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.41B | 11.59B | 83.79% |
| Dec 31, 2023 | 13.83B | -457.45B | -97.07% |
| Dec 31, 2022 | 471.27B | 149.44B | 46.44% |
| Dec 31, 2021 | 321.83B | 276.11B | 603.96% |
| Dec 31, 2020 | 45.72B | 36.57B | 399.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Jeil Pharma Holdings | 707.15B |
| ALTEOGEN | 202.18B |
| CKD Bio | 159.93B |
| DK Life Science | 131.17B |
| Shinhung | 98.94B |
| ABL Bio | 88.44B |